For years, hormone replacement therapy (HRT) carried a strict FDA black box warning explicitly linking it to an increased risk of breast cancer. If you’ve been hesitant to pursue medical relief for menopause symptoms because of that warning, your fear isn’t unfounded. However, over the last two decades, researchers reanalyzed the data and changed the medical consensus about HRT and breast cancer. The FDA has since removed breast cancer from the black box warning.

Read on to untangle the actual data behind the previous warning, understand your personal risk profile, and learn how modern hormone therapies offer a safe path to symptom relief.

Breast cancer risk with HRT: Where concerns stem from

The Women’s Health Initiative (WHI) study provides the bulk of the misleading historical data surrounding cancer risk with HRT. For years, the trial tracked over 16,000 postmenopausal women aged 50–79, dividing participants into two groups: One taking a combined estrogen-progestin pill and another taking a placebo. When researchers published these findings in the Journal of the American Medical Association (JAMA) in 2002, the data sparked immediate alarm.

Researchers stopped the trial early, after roughly five years, because they recorded elevated rates of breast cancer, heart disease, and blood clots in the hormone therapy group. While these findings were real, several crucial details complicate a straightforward reading of the data:

• Age: The average participant’s age was 63, more than a decade past the typical age of reaching menopause. The results may not reflect women who start HRT earlier. 
• Formulation: Researchers tested one specific oral tablet containing a synthetic progestin. This matters because synthetic progestins drive the increased breast cancer risk, which is why doctors rarely prescribe this formulation today.
• Regimen: Because the trial studied a single regimen, it didn’t demonstrate how risks differ across the various types of HRT available now. 

The gap between relative and absolute risk creates another layer of misunderstanding. Relative risk compares two groups to show a percentage change, which can make a tiny difference sound large. Absolute risk tells you the real-world chance of an event happening.

Headlines often highlight the alarming 26% relative risk increase reported by researchers. However, they rarely explain the absolute risk, which amounts to approximately eight extra cases per 10,000 women a year. 

The 2026 FDA label change: What does it mean?

The FDA responded to the 2002 findings by adding prominent safety alerts (black box warnings) to HRT product labels in 2003. The organization removed the warning in early 2026 after concluding the original data overstated the risk for most women using HRT. It also stripped warnings for cardiovascular disease and probable dementia. 

By lifting these black box warnings, the FDA removed a major barrier to care. It’s now easier for doctors to confidently prescribe HRT and for women to access symptom relief without unnecessary fear.

What the current evidence says

For most women, HRT safely and effectively eases menopause symptoms. While a risk of breast cancer exists, modern evidence shows that the absolute increase is remarkably small.

The most important takeaway from this newer research is that risk isn’t uniform. Rather than a one-size-fits-all danger, your statistical risk depends on the specific HRT formulation, delivery method, and treatment duration.

Leading medical authorities like The Menopause Society (NAMS) and the American College of Obstetricians and Gynecologists (ACOG) favor HRT for healthy women under 60 or within 10 years of menopause. For these groups, the benefits of symptom relief outweigh the statistical risks.

What affects breast cancer risk? 

Several factors shape the risk of HRT and breast cancer. Here’s what you need to know.

Hormone type

The specific combination of hormones you take determines the baseline safety of your treatment: 

• Estrogen-only therapy (ET) contains estrogen alone. Doctors prescribe this for women who’ve had their uterus removed (hysterectomy), as unopposed estrogen can cause the uterine lining to thicken, which causes uterine cancer.
• Combined estrogen-progesterone therapy (EPT) contains both hormones. Doctors usually prescribe progesterone alongside estrogen to protect people with a uterus from uterine cancer.

Does estrogen increase risk of breast cancer?

The data shows that estrogen alone carries little to no increased risk of breast cancer. Instead, research points to synthetic progesterone (progestin) as the primary driver of increased breast cancer risk in combined HRT. 

One proposed mechanism is that progesterone signaling increases VEGF, a protein that can promote tumor growth. Synthetic progestins are chemically changed versions of the hormone. Because they aren’t a perfect match, they can plug into the wrong cellular switches, like cortisol and androgen receptors, which triggers a spike in VEGF production. Because of this, doctors prefer prescribing a body-identical form of progesterone (called micronized progesterone). This form is an exact match to your body, so it only fits in the correct switches, keeping VEG signaling at a normal baseline. 

Delivery method

How the hormones enter your body dictates whether they affect your entire system or just a targeted area:

• Systemic HRT delivers hormones into the bloodstream to treat whole-body symptoms like hot flashes and night sweats. This includes oral pills, transdermal patches, and gels. Combined HRT carries a slightly higher breast cancer risk than estrogen-only therapy.
• Local HRT delivers low-dose estrogen to a specific area to relieve a localized symptom like vaginal dryness. Delivery methods include creams, inserts, and rings. Because virtually none of the hormone enters the bloodstream, local HRT carries little to no risk.

Treatment schedule and duration

The timing of your dose and the total number of years you stay on therapy directly influences cumulative risk:

• The schedule: Doctors prescribed combined therapy in one of two ways: continuous (taking both hormones daily) or sequential (taking estrogen daily and adding progesterone for part of the month). Continuous cycles carry a slightly higher risk than sequential ones.
• The duration: Risk builds steadily with each year of treatment. While short-term use under one year carries virtually no breast cancer risk, the probability increases over several years of use. A study published in the British Medical Journal (BMJ) showed that for a 50-year-old woman, five years of combined HRT use increases the lifetime risk of developing breast cancer from 6.1% to 6.7%. Once you stop therapy, the risk returns to your personal baseline within a few years.

Family history of breast cancer

Having a first-degree relative (like a mother or sister) with breast cancer roughly doubles your lifetime risk before beginning HRT. If you’re considering HRT and have a family history of breast cancer, the first step is to discuss this with your doctor. These questions can help guide the conversation: 

• Personal risk factors: Given my history, are there certain forms of HRT that place me at greater risk?
• Risk mitigation: How can we minimize risk while still supporting symptom relief? 
• Alternative treatments: Should I consider a non hormonal intervention instead? 
• Risk assessment: What tests do you recommend that can help determine my breast cancer risk?
• Ongoing monitoring: If I start HRT, how would we monitor for any changes in risk? 

Nonhormonal treatment options

When medical history or personal preference rule out hormones, these are just some of the nonhormonal therapies that may offer relief:

• Low-dose antidepressants (SSRIs and SNRIs): While traditionally used for mental health, these medications help the brain regulate body temperature by stabilizing the levels of serotonin and norepinephrine. In menopause, the brain’s thermostat becomes overly sensitive, misinterpreting small temperature changes as overheating. By keeping these chemical messengers steady, SSRIs and SNRIs prevent the brain from mistakenly triggering a cooling response (hot flash) when your body’s at a normal temperature.
• Vaginal moisturizers: Over 40% of women experience vaginal dryness, thinning, and irritation (genitourinary syndrome of menopause). Regular use of nonhormonal moisturizers binds directly to vaginal tissue to rehydrate it and restore comfort. 
• Neurokinin receptor antagonists: These medications block a signal in the brain called neurokinin B. In a healthy state, your brain maintains a stable body temperature, but the drop in estrogen during menopause causes these neurokinin B signals to become hyperactive. These signals act like a faulty alarm, telling your brain it’s overheating. By blocking these signals, medications like Veozah (fezolinetant) and Lynkuet (elinzanetant) silence the alarm and stop hot flashes.

How Maven Clinic’s Hormone Care can help you

Deciding on HRT can feel daunting, but for most women, hormone therapy is a completely safe treatment. Modern research confirms that breast cancer risks remain much lower than studies once suggested. And the improvements in daily health and well-being often far outweigh the potential risks. But you don’t have to navigate your decision alone. 

That’s why millions of women turn to Maven Clinic. We connect you with a team spanning more than 30 specialties, including OB-GYNs, reproductive endocrinologists, and mental health providers. With 24/7 virtual access to your care team, you’ll get the clinical expertise and peace of mind you need to confidently choose your path forward.

Discover our approach to hormone care.

FAQ

What can I take instead of HRT after breast cancer?

If you’re navigating life after breast cancer, nonhormonal treatments are the safest path forward. Because these targeted therapies don’t introduce estrogen to your system, they allow you to safely manage menopause symptoms without impacting your cancer recovery care plan.

Does breast cancer risk go back to normal after stopping HRT?

Yes, but it takes time. The elevated risk associated with long-term HRT use begins to decline as soon as you stop the therapy. However, large-scale tracking data shows that some excess risk can linger for up to 10 years after discontinuation. 

Is micronized progesterone safer than synthetic progestins for breast cancer risk?

Yes. According to research published in Systematic Reviews, body-identical micronized progesterone doesn’t carry the same increased breast cancer risk as older synthetic progestins when used for up to five years. Because of this improved safety profile, menopause societies now widely recommend micronized progesterone as the preferred choice for combined HRT.